Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gross Profit: 2021-2024

Historic Gross Profit for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $108.3 million.

  • Amylyx Pharmaceuticals' Gross Profit fell 77.63% to $26.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $110.4 million, marking a year-over-year decrease of 72.82%. This contributed to the annual value of $108.3 million for FY2024, which is 73.32% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Gross Profit of $108.3 million as of FY2024, which was down 73.32% from $406.0 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Gross Profit ranged from a high of $406.0 million in FY2023 and a low of $285,000 during FY2021.
  • Moreover, its 3-year median value for Gross Profit was $108.3 million (2024), whereas its average is $179.5 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Gross Profit skyrocketed by 8,360.00% in 2022 and then crashed by 73.32% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Gross Profit stood at $285,000 in 2021, then soared by 8,360.00% to $24.1 million in 2022, then skyrocketed by 1,583.85% to $406.0 million in 2023, then crashed by 73.32% to $108.3 million in 2024.